Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib

• Main Authors: Michele Manganelli, Ilaria Grossi, Manuela Ferracin, Paola Guerriero, Massimo Negrini, Michele Ghidini, Chiara Senti, Margherita Ratti, Claudio Pizzo, Rodolfo Passalacqua, Sarah Molfino, Gianluca Baiocchi, Nazario Portolani, Eleonora Marchina, Giuseppina De Petro, Alessandro Salvi
• Format: Article
• Language: English
• Published: MDPI AG 2021-07-01
• Series: Biomedicines
• Subjects: HCC; sorafenib; ddPCR; GAS5; miR-126-3p; miR-23b-3p
• Online Access: https://www.mdpi.com/2227-9059/9/7/813

Human hepatocellular carcinoma (HCC) is the most frequent primary tumor of the liver and the third cause of cancer-related deaths. The multikinase inhibitor sorafenib is a systemic drug for unresectable HCC. The identification of molecular biomarkers for the early diagnosis of HCC and responsiveness to treatment are needed. In this work, we performed an exploratory study to investigate the longitudinal levels of cell-free long ncRNA GAS5 and microRNAs miR-126-3p and -23b-3p in a cohort of 7 patients during the period of treatment with sorafenib. We used qPCR to measure the amounts of GAS5 and miR-126-3p and droplet digital PCR (ddPCR) to measure the levels of miR-23b-3p. Patients treated with sorafenib displayed variable levels of GAS5, miR-126-3p and miR-23b-3p at different time-points of follow-up. miR-23b-3p was further measured by ddPCR in 37 healthy individuals and 25 untreated HCC patients. The amount of miR-23b-3p in the plasma of untreated HCC patients was significantly downregulated if compared to healthy individuals. The ROC curve analysis underlined its diagnostic relevance. In conclusion, our results highlight a potential clinical significance of circulating miR-23b-3p and an exploratory observation on the longitudinal plasmatic levels of GAS5, miR-126-3p and miR-23b-3p during sorafenib treatment.